Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.13 Million CNY | 995.1% |
| 2022 | 469 Thousand CNY | -72.15% |
| 2021 | 1.68 Million CNY | -36.26% |
| 2020 | 2.64 Million CNY | 63.9% |
| 2019 | 1.61 Million CNY | 0.0% |
| 2018 | - CNY | -100.0% |
| 2017 | 110 Thousand CNY | -88.42% |
| 2016 | 950 Thousand CNY | -38.71% |
| 2015 | 1.55 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.88 Million CNY | -43.91% |
| 2024 Q2 | 2.88 Million CNY | 60.47% |
| 2023 Q4 | 5.13 Million CNY | 0.0% |
| 2023 Q2 | 1.94 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 5.13 Million CNY | 995.1% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 469 Thousand CNY | -72.15% |
| 2022 Q4 | 469 Thousand CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 1.09 Million CNY | 0.0% |
| 2021 Q2 | 2.63 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 1.68 Million CNY | -36.26% |
| 2021 Q4 | 1.68 Million CNY | 0.0% |
| 2020 Q4 | 2.64 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 2.64 Million CNY | 63.9% |
| 2020 Q2 | 1.08 Million CNY | 0.0% |
| 2019 Q2 | 228 Thousand CNY | 0.0% |
| 2019 Q4 | 1.61 Million CNY | 0.0% |
| 2019 FY | 1.61 Million CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 FY | - CNY | -100.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2017 FY | 110 Thousand CNY | -88.42% |
| 2016 FY | 950 Thousand CNY | -38.71% |
| 2015 FY | 1.55 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | 24.581% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 99.849% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 95.735% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 98.886% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -954.62% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 97.484% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 98.253% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 98.461% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 98.791% |
| SSY Group Limited | 3.37 Billion HKD | 99.848% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 96.15% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 99.315% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.994% |